SMARCA4 and renal cell carcinoma: The data presented by Reig Torras and colleagues [43] indicate that analysis of mutations in both the Tp53 and SMARCA4 genes could help select RCC patients for active surveillance, which gives patients more comfort in their lives by avoiding or at least delaying the need for chemotherapy or surgery.